financetom
Business
financetom
/
Business
/
Metlife Insider Sold Shares Worth $289,479, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Metlife Insider Sold Shares Worth $289,479, According to a Recent SEC Filing
Mar 14, 2024 2:06 PM

04:41 PM EDT, 03/14/2024 (MT Newswires) -- Ramy Tadros, President, US Business, on March 13, 2024, sold 4,026 shares in Metlife ( MET ) for $289,479. Following the Form 4 filing with the SEC, Tadros has control over a total of 146,981 shares of the company, with 146,981 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1099219/000109921924000076/xslF345X03/wk-form4_1710448537.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Hope Therapeutics and NRx Pharmaceuticals to Acquire Interest in Cohen and Associates for Psychiatry Clinics
BRIEF-Hope Therapeutics and NRx Pharmaceuticals to Acquire Interest in Cohen and Associates for Psychiatry Clinics
Jun 26, 2025
June 26 (Reuters) - NRX Pharmaceuticals Inc ( NRXP ): * HOPE THERAPEUTICS, INC. AND NRX PHARMACEUTICALS, INC. ( NRXP ) ANNOUNCE AGREEMENT TO ACQUIRE INTEREST IN COHEN AND ASSOCIATES, LLC FOR HOPE'S NETWORK OF INTERVENTIONAL PSYCHIATRY CLINICS * NRX PHARMACEUTICALS INC ( NRXP ) - HOPE TO PURCHASE 49% INTEREST IN COHEN AND ASSOCIATES * NRX PHARMACEUTICALS INC (...
Alto Neuroscience Identifies Biomarker in Phase 2 Trial for Major Depressive Disorder Patients
Alto Neuroscience Identifies Biomarker in Phase 2 Trial for Major Depressive Disorder Patients
Jun 26, 2025
08:16 AM EDT, 06/26/2025 (MT Newswires) -- Alto Neuroscience ( ANRO ) said Thursday it was able to identify a patient selection biomarker in its exploratory phase 2 proof-of-concept trial of ALTO-203 in major depressive disorder patients with elevated levels of anhedonia. ALTO-203 demonstrated clear effects on objective measures of attention and wakefulness, in the phase 2 trial, the company...
Hapbee to Raise $1.5 Million in Private Placement
Hapbee to Raise $1.5 Million in Private Placement
Jun 26, 2025
08:19 AM EDT, 06/26/2025 (MT Newswires) -- Hapbee Technologies ( HAPBF ) , which gained 18% on Wednesday, overnight, announced a non-brokered private placement consisting of up to 15.1 million units at $0.10 apiece for $1.5 million. The company also appointed Ahsan Ashraf as its new chief technology officer. Each Unit will consist of one subordinate voting common share and...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved